Skip to content

About SMA:

SMA Press

aboutsma

About SMA: SMA Press

Partnership between SMA Foundation, PTC Therapeutics, and Roche featured in article

September 28, 2020

Following the approval of Evrysdi, Roche released an article describing its partnership with the SMA Foundation and PTC Therapeutics to develop the drug. To read the article, please visit: https://www.roche.com/partnering/spinal-muscular-atrophy-sma-together.htm

Read More

Arya Singh featured in New Haven Register article

September 20, 2020

Arya Singh, an SMA patient and Yale University student, was featured in a New Haven Register article on September 19th. In the article, Singh describes the challenges she faces as a patient and her experiences in clinical trials. To view the article, please visit: https://www.ctinsider.com/news/nhregister/article/This-Yale-student-won-t-let-a-rare-genetic-15579131.php?src=nhrhpcp To view a photo essay for the article, please visit:…

Read More

SMA News Today publishes a series of articles on Evrysdi discovery and development

September 20, 2020

In August, SMA News Today published a series of articles on the discovery and development of Evrysdi, the first and only oral medicine for SMA approved by the FDA. The articles cover a range of topics including the role of the SMA Foundation in drug development, the experiences of patients taking Evrysdi, and the future…

Read More

SMA featured in WuXi AppTec’s “Collaborations That Transform” webinar series

September 20, 2020

As part of its “Collaborations That Transform” webinar series, WuXi AppTec hosted three panels of distinguished SMA experts, representing patient, industry and physician perspectives. The panelists discussed the current state of SMA therapies and the promise of the next generation of treatment approaches. To view the webinar please visit: https://wxpress.wuxiapptec.com/webinar-sma/

Read More

FDA approves Evrysdi (risdiplam) for treatment of Spinal Muscular Atrophy (SMA) in adults and children 2 months and older

August 7, 2020

The SMA Foundation’s partners, Roche and PTC Therapeutics, announced today that Evrysdi™ (risdiplam) was approved by the U.S. Food and Drug Administration (FDA) for the treatment of Spinal Muscular Atrophy (SMA) in adults and children two months and older. Evrysdi showed clinically meaningful improvements in motor function across two clinical trials covering a broad range…

Read More

Risdiplam meets primary endpoint in pivotal FIREFISH trial in infants with Type 1 SMA

January 23, 2020

The SMA Foundation’s partners, Roche and PTC Therapeutics, announced positive data from the pivotal Part 2 of FIREFISH, a study evaluating risdiplam in infants aged 1-7 months with Type 1 SMA. The study met its primary endpoint of a statistically significant proportion of infants sitting without support for at least five seconds after one year…

Read More

Scholar Rock announces completion of TOPAZ trial enrollment

January 10, 2020

Scholar Rock announced today that enrollment of its TOPAZ Phase 2 trial of SRK-015 in patients with Type 2 and Type 3 SMA is complete. SRK-015 is a selective inhibitor of myostatin that has been shown to increase muscle mass and strength in animal models. For more information, please see the press release from Scholar…

Read More

Cerebrum podcast features SMA researcher Lee Rubin discussing recent advances in SMA therapeutics

April 5, 2019

SMA researcher and Harvard University professor Lee Rubin was featured in a podcast with Bill Glovin from the Dana Foundation to talk about the recent Cerebrum article he co-authored, “Spinal Muscular Atrophy: Huge Steps.” Both the article and podcast discuss recent advances in SMA therapeutics. To listen to the podcast, please visit: https://soundcloud.com/danafoundation/spinal-muscular-atrophy-huge-steps

Read More

Novartis announces FDA filing acceptance and Priority Review of AVXS-101, a one-time treatment designed to address the genetic root cause of SMA Type 1

December 3, 2018

Basel, December 3, 2018 – Novartis today announced that the U.S. Food and Drug Administration (FDA) has accepted the company’s Biologics License Application (BLA) for AVXS-101, now known as ZOLGENSMA® (onasemnogene abeparvovec-xxxx), an investigational gene replacement therapy for the treatment of spinal muscular atrophy (SMA) Type 1. ZOLGENSMA is designed to address the genetic root cause of…

Read More

Scholar Rock Announces Publication of Preclinical Data on the Therapeutic Benefit of Inhibiting Myostatin Activation in Models of Spinal Muscular Atrophy

December 3, 2018

CAMBRIDGE, Mass., Nov. 27, 2018 (GLOBE NEWSWIRE) — Scholar Rock Holding Corporation (NASDAQ: SRRK), a clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which protein growth factors play a fundamental role, today announced the publication, “Specific Inhibition of Myostatin Activation is Beneficial in Mouse Models of SMA Therapy” in the peer-reviewed journal Human Molecular Genetics. The publication details…

Read More

SMA researchers Frank Bennett and Adrian Krainer win the prestigious Breakthrough Prize

October 19, 2018

Excerpted from Breakthrough Prize press release:   A Total of $22 Million Awarded for Breakthroughs in Treatment for the Leading Genetic Cause of Infant Death, Super-Resolution Imaging, Discovery of a New Kind of Electronic Material, and Other Major Achievements.  2019 Breakthrough Prize in Life Sciences Awarded to C. Frank Bennett and Adrian R. Krainer.  All…

Read More

The Spinal Muscular Atrophy Foundation Rings Nasdaq Opening Bell

August 18, 2018

The Spinal Muscular Atrophy (SMA) Foundation, a non-profit, organization whose mission is to accelerate the development of treatments for SMA, the leading cause of genetic death in young children, visited the Nasdaq MarketSite in Times Square on August 17, 2018. In honor of the occasion, Dinakar Singh, Co-Founder and Chairman of the Board of Directors,…

Read More
Scroll To Top